急性冠脉综合征后常规通知CYP2C19代谢状态对P2Y12抑制剂转换的影响
本研究基于GEMINI-ACS-1试验,在3037例急性冠脉综合征患者中,调查强制报告CYP2C19药物基因组检测结果(无直接使用建议)与P2Y12抑制剂转换的关联。结果显示,医生对氯吡格雷治疗患者的CYP2C19代谢状态反应不一,强制提供信息很少促使P2Y12抑制剂转换,包括代谢减弱患者中的少数。
要点
- 强制报告CYP2C19代谢状态后,总体P2Y12抑制剂转换率低,仅197例转换。
- 氯吡格雷初始治疗患者中,因代谢状态转换者占1.7%,代谢减弱者中仅31.3%转换。
- 替格瑞洛初始治疗患者中,仅1例基于CYP2C19状态转换。
核心结论
- 医生对氯吡格雷治疗患者的CYP2C19代谢状态反应不一,强制提供该信息很少促使P2Y12抑制剂转换。
研究设计与样本
- 基于GEMINI-ACS-1随机临床试验,纳入21个国家371个中心的3037例急性冠脉综合征患者。
- 研究者预先规定对CYP2C19代谢状态的计划反应,随机后约1周强制报告所有患者结果。
主要发现
- 初始治疗:1704例(56.1%)使用替格瑞洛,1333例(43.9%)使用氯吡格雷。
- 任何原因P2Y12抑制剂转换发生在197例患者,替格瑞洛组146/1704(8.6%)高于氯吡格雷组51/1333(3.8%)。
- 氯吡格雷初始治疗患者中,23例(1.7%总体,45.1%转换者)因代谢状态转换;替格瑞洛初始治疗患者中仅1例(0.1%总体,0.7%转换者)基于CYP2C19状态转换。
- 48例(3.6%)代谢减弱患者初始用氯吡格雷,其中15例(31.3%)因代谢状态转换,包括13/27(48.1%)为预先规定转换。
关键数值与推荐
- 研究者预先规定:642/1324(48.5%)基因分型氯吡格雷治疗患者和93/1692(5.5%)基因分型替格瑞洛治疗患者将使用CYP2C19代谢状态改变P2Y12抑制剂。
临床怎么用
- 常规CYP2C19基因分型结果强制报告未显著改变P2Y12抑制剂选择,尤其替格瑞洛治疗者。
- 对氯吡格雷治疗且代谢减弱患者,部分医生仍选择转换,但整体转换率低,反映临床均势。
局限性
- 缺乏 definitive 临床试验数据证明基于常规基因分型调整治疗的 efficacy。
- 医生对CYP2C19信息反应存在均势,且无直接使用建议,可能影响转换率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Physician behavior in response to knowledge of a patient's CYP2C19 clopidogrel metabolizer status is unknown. OBJECTIVE: To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial. DESIGN, SETTING, AND PARTICIPANTS: The GEMINI-ACS-1 trial compared rivaroxaban, 2.5 mg twice daily, with aspirin, 100 mg daily, plus open-label clopidogrel or ticagrelor (provided), in patients with recent acute coronary syndromes (ACS). The trial included 371 clinical centers in 21 countries and 3037 patients with ACS. Data were analyzed between May 2017 and February 2019. INTERVENTIONS: Investigators were required to prestipulate their planned response to CYP2C19 metabolizer status. In response to a regulatory mandate, results for all patients were reported to investigators approximately 1 week after randomization. MAIN OUTCOMES AND MEASURES: Reasons for switching P2Y12 inhibitors and occurrence of bleeding and ischemic events were collected. RESULTS: Of 3037 patients enrolled (mean [SD] age, 62.8 [9.0] years; 2275 men [74.9%], and 2824 white race/ethnicity [93.0%]), investigators initially treated 1704 (56.1%) with ticagrelor and 1333 (43.9%) with clopidogrel. Investigators prestipulated that they would use CYP2C19 metabolizer status to change P2Y12 inhibitor in 48.5% of genotyped clopidogrel-treated patients (n = 642 of 1324) and 5.5% of genotyped ticagrelor-treated patients (n = 93 of 1692). P2Y12 inhibitor switching for any reason occurred in 197 patients and was more common in patients treated with ticagrelor (146 of 1704 [8.6%]) compared with clopidogrel (51 of 1333 [3.8%]). Of patients initially treated with ticagrelor, only 1 (0.1% overall; 0.7% of all who switched) was switched based on CYP2C19 status. Of patients initially treated with clopidogrel, 23 (1.7% overall,;45.1% of all who switched) were switched owing to metabolizer status. Of 48 patients (3.6%) with reduced metabolizer status treated initially with clopidogrel, 15 (31.3%) were switched based on metabolizer status, including 48.1% (13 of 27) in which switching was prestipulated. CONCLUSIONS AND RELEVANCE: Physicians were evenly split on how to respond to knowledge of CYP2C19 metabolizer status in clopidogrel-treated patients. Mandatory provision of this information rarely prompted P2Y12 inhibitor switching overall, including a minority of patients with reduced metabolizer status. These findings highlight the clinical equipoise among physicians regarding use of this information and the reluctance to use information from routine genotyping in the absence of definitive clinical trial data demonstrating the efficacy of this approach. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02293395.
引用
- Povsic TJ, Ohman EM, Roe MT, et al. P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiol. 2019. PMID: 31141104. doi:10.1001/jamacardio.2019.1510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。